PD-1/PD-L1 interaction
PD-1/PD-L1 interaction(PD-1/PD-L1 相互作用)
Programmed death-1 (PD-1) is a receptor on T cells that has been shown to suppress activating signals from the T cell receptor when bound by either of its ligands, Programmed death-ligand 1 (PD-L1) or PD-L2. When PD-1 expressing T cells contact cells expressing its ligands, functional activities in response to antigenic stimuli, including proliferation, cytokine secretion, and cytotoxicity are reduced. PD-1/PD-Ligand interactions down regulate immune responses during resolution of an infection or tumor, or during the development of self tolerance.
Interference with the PD-1/PD-L1 interaction has also shown enhanced T cell activity in chronic infection systems. Chronic lymphocytic chorio meningitis virus infection of mice also exhibits improved virus clearance and restored immunity with blockade of PD-L1.
In addition to enhancing immunologic responses to chronic antigens, blockade of the PD-1/PD-L1 pathway has also been shown to enhance responses to vaccination, including therapeutic vaccination in the context of chronic infection.
PD-1/PD-L1 interaction 相关产品(90)
- GC74532TuvonralimabCAS: 2417649-44-4纯度: >99.00%
Tuvonralimab (psb - 205;QL1706)是一种双免疫检查点阻断剂,含有抗pd -1 IgG4和抗ctla -4 IgG1抗体的混合物,Iparomlimab和Tuvonralimab。
- GC74543EzabenlimabCAS: 2249882-54-8纯度: >99.00%
Ezabenlimab (BI-754091)是一种抗pd -1单抗,结合常数Kd值为6 nM (CHO细胞)。
- GC74553GeptanolimabCAS: 2348469-43-0纯度: >97.00%
Geptanolimab(CBT-501)是一种针对程序性死亡-1(PD-1)的人源化IgG4k单克隆抗体。
- GC74568LatikafuspCAS: 2552814-07-8纯度: >99.00%
Latikafusp (AMG 256)是一种双功能融合蛋白,包括PD-1靶向抗体和IL-21突变蛋白,旨在向PD-1+细胞提供IL-21通路刺激。
- GC74601CosibelimabCAS: 2216751-26-5纯度: >99.00%
Cosibelimab (ck - 301;TG-1501)是一种高亲和力的全人源性PD-L1阻断单克隆抗体,可结合PD-L1并阻断其与PD-1的相互作用。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC74532 | Tuvonralimab | 2417649-44-4 | >99.00% | |
Tuvonralimab (psb - 205;QL1706)是一种双免疫检查点阻断剂,含有抗pd -1 IgG4和抗ctla -4 IgG1抗体的混合物,Iparomlimab和Tuvonralimab。 | ||||
| GC74534 | Tagitanlimab | 2417649-97-7 | >99.00% | |
Tagitanlimab (HBM-9167)是一种人源抗pd - l1抗体(IgG1κ型)。 | ||||
| GC74541 | Socazolimab | 2305043-30-3 | >98.00% | |
Socazolimab(ZKAB001)是一种抗PD-L1单克隆抗体。 | ||||
| GC74543 | Ezabenlimab | 2249882-54-8 | >99.00% | |
Ezabenlimab (BI-754091)是一种抗pd -1单抗,结合常数Kd值为6 nM (CHO细胞)。 | ||||
| GC74553 | Geptanolimab | 2348469-43-0 | >97.00% | |
Geptanolimab(CBT-501)是一种针对程序性死亡-1(PD-1)的人源化IgG4k单克隆抗体。 | ||||
| GC74556 | Gilvetmab | 1808081-43-7 | >99.00% | |
Gilvetmab是一种有效的犬化抗pd -1单克隆抗体。Gilvetmab阻断PD-1与其配体PDL-1的相互作用。 | ||||
| GC74564 | Ivonescimab | 2428381-53-5 | >97.50% | |
Ivonescimab (AK112)是一种PD-1/VEGF双特异性抗体。 | ||||
| GC74568 | Latikafusp | 2552814-07-8 | >99.00% | |
Latikafusp (AMG 256)是一种双功能融合蛋白,包括PD-1靶向抗体和IL-21突变蛋白,旨在向PD-1+细胞提供IL-21通路刺激。 | ||||
| GC74583 | Nofazinlimab | 2377845-98-0 | >98.00% | |
Nofazinlimab (CS1003)是一种人源IgG4抗pd -1单克隆抗体。 | ||||
| GC74592 | Pacmilimab | 2145091-51-4 | >95.00% | |
Pacmilimab (CX-072)是一种有效的PD-L1抑制剂。 | ||||
| GC74595 | Prolgolimab | 2093956-19-3 | 不显示 | |
Prolgolimab(BCD-100)是一种含有Fc沉默“LALA”突变的人IgG1抗PD-1单克隆抗体。 | ||||
| GC74601 | Cosibelimab | 2216751-26-5 | >99.00% | |
Cosibelimab (ck - 301;TG-1501)是一种高亲和力的全人源性PD-L1阻断单克隆抗体,可结合PD-L1并阻断其与PD-1的相互作用。 | ||||
| GC74611 | Peresolimab | 2411580-63-5 | >99.00% | |
Peresolimab是一种靶向PD-1的人源化IgG1-κ抗体。 | ||||
| GC74616 | Retifanlimab | 2079108-44-2 | >96.00% | |
Retifanlimab是一种抗程序性细胞死亡蛋白1 (anti-PD-1)单克隆抗体。 | ||||
| GC74617 | SHR-1701 | 2891860-17-4 | >99.00% | |
SHR-1701(Retlirafusp alfa)是一种用于癌症研究的靶向PD-L1和TGF-β的双功能融合蛋白。 | ||||
| GC74623 | Reozalimab | 2445259-99-2 | >99.00% | |
Reozalimab是一种靶向PD-1/PD-L1的双特异性抗体。 | ||||
| GC74627 | Rosnilimab | 2412764-40-8 | >99.00% | |
Rosnilimab是一种靶向PD-1的人源化IgG1-κ抗体。 | ||||
| GC74719 | ASC-69 | 1216665-50-7 | >99.00% | |
ASC-69(APY69)是一种有效且有前景的PD-1/PD-L1小分子抑制剂。 | ||||
